

EXHIBIT 9

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF ARKANSAS
CENTRAL DIVISION**

FREDERICK W. HOPKINS, M.D., M.P.H. et
al.,

Plaintiffs,

v.

LARRY JEGLEY, et al.,

Defendants.

CIVIL ACTION

Case No. 4:17-CV-00404-KGB

**DECLARATION OF KATHARINE D. WENSTROM, M.D. IN SUPPORT OF
PLAINTIFFS' SECOND MOTION FOR A PRELIMINARY INJUNCTION AND/OR
TEMPORARY RESTRAINING ORDER**

I, Katharine D. Wenstrom, M.D., pursuant to 28 U.S.C. §1746, declare under penalty of perjury that the following is true and correct:

1. I am a physician licensed to practice medicine in the state of Rhode Island. I received my medical degree from Case Western Reserve University School of Medicine, and completed a residency in obstetrics and gynecology (“OBGYN”) and a fellowship in maternal-fetal medicine at the University of Illinois in Chicago Hospital. I then completed a second fellowship in medical genetics at the University of Iowa Hospital.

2. I have been Board Certified by the American Board of Obstetrics and Gynecology in OBGYN since 1992 and in Maternal-Fetal Medicine since 1994, and by the American Board of Medical Genetics since 1990. I am currently a Professor of Medical Science at the Warren Alpert Medical School of Brown University. I was previously a professor of OBGYN and the director of the Division of Maternal-Fetal Medicine at Women & Infants Hospital of Rhode Island, as well as director of Prenatal Genetics. I have served as the president of the Society for

Maternal-Fetal Medicine, and have been a member of the executive board of the American College of Obstetricians and Gynecologists. I have published more than 100 peer-reviewed research papers, as well as a variety of articles, commentaries, and book chapters on topics in maternal-fetal medicine and genetics.

3. My current *curriculum vitae*, which more fully sets forth my experience and credentials, is attached as Exhibit A.

4. I have reviewed the declarations of Lori Williams and Dr. Willie Parker. I understand based on those declarations that none of the physicians who provide abortion care at Little Rock Family Planning Services have training or experience with using potassium-chloride (“KCl”) injections to induce fetal demise.

THE BAN ON D&E AND KCl INJECTIONS

5. I have reviewed Act 45 (the “D&E Ban” or the “Ban”). Based on my training and experience, it is my opinion that, as written, this law bans dilatation and evacuation (“D&E”) abortion procedures.

6. I understand that the State has argued that injection of KCl is a safe and effective means for physicians who provide abortion care in Arkansas to ensure fetal demise before performing a D&E and thereby circumvent the Ban. I adamantly disagree.

Background Relating To The Use Of KCl Injections

7. Some physicians with advanced training are capable of inducing fetal demise using intracardiac (fetal) administration of KCl via a transabdominal injection performed with ultrasound guidance. To cause demise, KCl is rapidly injected in the fetal heart using a 7-to-9-inch needle that must be guided extremely carefully through the patient’s abdominal and uterine walls, into the uterus and amniotic fluid, and then into the fetal chest and directly into the fetal

heart. Ultrasound is thereafter used to confirm asystole (no cardiac activity). If there are no complications, the entire procedure, start to finish, typically takes approximately 60 minutes. Due to dilution, KCl will not cause fetal demise when injected into amniotic fluid; injection into the fetal heart is required to safely and effectively perform the procedure.

8. The fetal heart is approximately the size of a pea at 14 weeks into a pregnancy after a patient's last menstrual period ("LMP"), and roughly the size of an olive at 20 weeks LMP.

9. KCl injections are typically used in the context of selective termination in a multi-fetal pregnancy, i.e., when a person is pregnant with more than one fetus and wishes to reduce the risk of preterm birth, or when one fetus has an anomaly. Multifetal pregnancy reduction generally confers medical benefits by reducing the risks associated with multifetal gestation.

10. I have performed approximately 200 intracardiac KCl injections, including approximately 50 for patients who were in the second trimester of their pregnancy at the time of the procedure.

Training Required for KCl Injections

11. An intracardiac injection of KCl is nearly 100% effective in inducing fetal demise, but the procedure requires an extremely high level of skill, and is thus almost exclusively performed by OBGYNs who are specialists in maternal-fetal medicine ("MFM"). MFM is an OBGYN sub-specialty involving an additional three-year training program after residency with extensive, advanced training at a major medical center and a focus on high-risk pregnancies. Training to perform KCl injections is not included in OBGYN residency training, and KCl-injection training is included in only a few MFM programs.

12. Admission to MFM fellowship programs is extremely competitive, and

fellowships are full-time obligations. Acceptance into an MFM program, however, does not guarantee that a physician will receive KCl-injection training. Physicians must seek out specific MFM programs with tertiary Fetal Therapy Centers (e.g., in New York, Philadelphia, or Texas) if they are interested in obtaining the training necessary to perform intracardiac KCl injections.

13. Moreover, training in and competence to perform KCl injections has become increasingly rare and difficult to obtain in recent years, because the high-order multifetal pregnancies that were common from the 1980s to the early 2000s have become less common in view of (among other things) advances in in-vitro fertilization laboratory techniques.

14. Before a physician can be trained to competently perform KCl injections, the clinician must obtain advanced ultrasound training, which is not generally available in Family Practice or OBGYN residencies. During a Family Practice residency, residents usually learn only certain limited ultrasound skills, such as dating a pregnancy, confirming the intrauterine location of the pregnancy (e.g., to rule out an ectopic pregnancy), or determining fetal position. OBGYN residents learn only a few additional skills, such as evaluation of placental location or rudimentary evaluation of fetal anatomy. KCl injections, however, require a physician to use a two-dimensional ultrasound image to visualize and guide a needle through three-dimensional maternal and fetal structures, while the fetus is moving. During my MFM fellowship, I received hundreds of hours of highly specialized ultrasound training that served as a necessary foundation for KCl-injection training.

15. During my maternal fetal medicine fellowship, I was trained to do two advanced ultrasound guided needle procedures that were essential to acquiring the skills required for more technically difficult KCl injections. Specifically, I was first trained to perform (i) genetic amniocentesis (a procedure done in the early second trimester in which a fine needle is inserted

through the maternal abdomen and into the uterus under ultrasound guidance in order to remove amniotic fluid for genetic testing of the fetus) with approximately 40 to 50 training procedures; and then (ii) cordocentesis (a second or early-third trimester procedure in which a needle is inserted into the umbilical cord under ultrasound guidance to obtain a fetal blood sample for testing) with approximately 20 to 30 procedures after achieving mastery of genetic amniocentesis. During my medical genetics fellowship, I then assisted a mentor in performing intracardiac KCl injections before performing the procedure myself, under his supervision.

16. A physician who does not have experience performing many dozens of ultrasound-guided needle procedures (such as the genetic amniocentesis and cordocentesis procedures described above) would first need to become expert in performing prenatal ultrasound exams, and then need to perform at least 30 to 40 KCl injections under the direct supervision of a trained expert before he or she could be trained to competency and perform the procedure with confidence that it would not cause additional stress or risk to the patient or fetus.

17. In view of the relatively low volume of available KCl-injection procedures, I have been able over the course of the last 20 years to train only two MFM fellows in administering KCl injections, one of whom was not able to participate in enough procedures to be trained to competency. When I was on faculty from 2009-2018 at Women and Infant's Hospital (a tertiary women's hospital in Providence, Rhode Island that does 8,700 deliveries a year), I was the only physician trained in the procedure. I am not currently aware of any other physicians in Rhode Island who are trained in the procedure, and am aware of at most only two other physicians in the greater Boston area who are trained in the procedure.

18. It would be extremely difficult, if not impossible, for an OBGYN (even with advanced training in Family Planning) or a Family Medicine physician to obtain the training

necessary to safely and effectively perform intracardiac KCl injections in an outpatient setting:

- a. Any physician seeking KCl-injection training would need to take significant time off from his or her practice and, as discussed below, likely move to another part of the country (potentially uprooting their entire family to do so), which for many physicians would not be feasible from a financial or personal standpoint.
- b. He or she would also need to find a qualified MFM or medical-genetics OBGYN physician who is willing to provide the training and has a high enough case volume that he or she could train the physician to competency within a reasonable period of time. As described above, the number of such programs is quite limited. Moreover, I am not aware of any training programs in the country that would permit a physician to participate in the program solely to learn KCl injections; most physicians obtain KCl-injection training by completing a three-year MFM fellowship program.

19. Even if it were possible to obtain the necessary training and exposure, it is nevertheless possible that a physician still would not be able to acquire the skills to safely perform the procedure. Achieving competency in the procedures that OBGYNs and Family Medicine physicians routinely provide (including abortion procedures) does not necessarily mean that the physician will become competent to perform highly technical ultrasound-guided needle procedures like KCl injections. No matter their level of training, in my experience, certain physicians simply do not have the requisite hand-eye coordination and skill in ultrasonography necessary for KCl injections.

20. Moreover, a trained physician is not the only medical professional necessary to safely and effectively perform KCl injections. The procedure also requires the assistance of a

trained and sophisticated ultrasound technician, or another physician, who can accurately guide the ultrasound transducer so that the physician performing the injection has—at certain times—both hands available for the procedure. Even an otherwise highly qualified ultrasound technician is not necessarily experienced enough to support an MFM while performing an intracardiac KCl injection.

21. In a typical intracardiac KCl injection, the physician holds the needle in one hand and the ultrasound probe in the other, while either another experienced doctor or ultrasound technician helps adjust the ultrasound equipment as needed to optimize imaging of the needle and the target to assist in accurate needle guidance. Precise timing of the needle insertion is essential because the fetal position can change rapidly. When the needle reaches the fetal heart (after passing through the abdomen, uterus, amniotic sac, and fetal chest), the physician passes the probe to the fellow or ultrasound technician so that the physician can remove the stylet (i.e., the plug in the inside of a hollow needle), attach a syringe containing saline that is injected to confirm the location of the needle, then attach the syringe containing KCl, and then inject the solution under direct ultrasound visualization, all while ensuring no displacement of the needle during maternal or fetal movements. The needle must then be held in place for 2-3 minutes so that additional KCl can be administered if asystole is not confirmed.

Risks Associated With KCl Injections

22. Intracardiac KCl injections are associated with a number of maternal health risks that, in my opinion, are not justified in circumstances where a physician is performing the procedure solely to comply with the D&E Ban. For example:

- a. There are risks of maternal tissue damage and severe pain if the KCl is inadvertently injected into the uterine muscle, and maternal cardiac arrest if the

KCl is inadvertently injected into a maternal blood vessel.¹

- b. There are risks of infection or chorioamnionitis (a serious condition in which the membranes surrounding the fetus are infected by bacteria) resulting from the transfer of bacteria from the maternal skin surface into the uterus.
- c. Although it is unlikely if a KCl injection is performed by a trained physician, an unsuccessful procedure could result in sepsis or the need for a hysterectomy.

23. Additionally, KCl injections can be very complicated (or even impossible) in women with common conditions such as obesity or uterine fibroids, which increase the risks of the procedure.

- a. When a patient is obese, the clinician must use a longer needle for the injection. This requires clinicians to be even more precise as they guide the needle, which is further complicated by suboptimal visualization of fetal structures by ultrasound due to the increased thickness of the maternal abdominal wall. A reason one of the fellows I attempted to train in KCl injections could not be trained to competency is that many of the patients who presented for treatment were obese, and he was unable to perform the procedures—even under my supervision—in view of that complicating factor.
- b. If a patient has uterine fibroids (benign growths in the uterine wall), which as many as 50% of reproductive-age women do, accessing the uterus with a needle may be extremely difficult. Uterine fibroids can distort the uterine cavity, restrict fetal movement and positioning, and severely limit the angles or approaches available to the physician to reach the fetal heart. Pushing a needle through a

¹ G.A. Coke *et al.*, *Maternal Cardiac Arrest Associated with Attempted Fetal Injection of Potassium Chloride*, 13 INT’L J. OBSTETRIC ANESTHESIA 287 (2004). This case report also demonstrates the substantial risks associated with performing KCl injections without the appropriate ultrasound equipment and professionals.

fibroid would be extremely difficult and is not advised. If a fibroid restricts the fetus to an unapproachable position or blocks the fetal heart, the procedure is potentially impossible.

24. The procedure itself can be an upsetting and uncomfortable experience for the patient, especially in view of the size of the needle. This is relevant because a patient's pain tolerance and anxiety level may make the procedure even more difficult. The patient is awake throughout the procedure, and will feel pain when the needle penetrates the skin and the uterus. Although a local anesthetic can be used to numb the skin, uterine pain cannot be prevented. The uterus is a muscle that contracts when penetrated, and the patient will feel extreme cramping for at least the duration of the procedure. Some patients are unable to stay completely still for the duration of the procedure, or cannot tolerate the uterine cramping or even the penetration of the needle. Further, if a woman's breathing intensifies due to anxiety or fear during the procedure, this can alter fetal positioning, further interfering with the procedure and increasing its difficulty.

25. In the event that the initial procedure is unsuccessful, a second procedure must be performed. Undergoing the procedure twice is extremely physically and emotionally stressful for the patient, and subjects her to risks all over again. Continuing a pregnancy after an incomplete KCl injection could be dangerous and thus medically inappropriate, given the risks to maternal health and likely harm that would result to the fetus.

* * * *

26. In sum, KCl injections are not a feasible means for abortion providers at Little Rock Family Planning Services to ensure fetal demise before every D&E, and mandating use of the additional procedure would subject patients to increased risk of harm with no corresponding benefit. If a physician who is untrained and inexperienced in performing these procedures began

an intracardiac KCl injection and could not complete it—a scenario that, in my opinion, is extremely likely—the patient would be forced to endure another unnecessary procedure to seek to induce demise, continue her pregnancy (despite increased risks), or try to seek care in another state.

I declare under penalty of perjury that the foregoing is true and correct.

Executed this 16th day of November, 2020.

A handwritten signature in blue ink that reads "Katherine D. Wenstrom, M.D." The signature is written in a cursive style.

Katharine D. Wenstrom, M.D.

EXHIBIT A

CURRICULUM VITAE

KATHARINE D. WENSTROM, M.D.

CURRENT POSITION: Professor of Medical Science
The Alpert Medical School of Brown University
July 2018- present

PREVIOUS POSITIONS: Professor, Obstetrics & Gynecology
Director, Division of Maternal Fetal Medicine
Department of Obstetrics and Gynecology
Women's and Infant's Hospital of Rhode Island
The Alpert Medical School of Brown University
Providence Rhode Island
July 2009- July 2018

Professor, Obstetrics & Gynecology
Co-Director, Center for Advanced Maternal and Fetal Care
Departments of Pediatric Surgery and Obstetrics and Gynecology
Vanderbilt University School of Medicine
Nashville, Tennessee
August 2006- May 2009

Professor, Obstetrics & Gynecology
Director, Division of Reproductive Genetics and
Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
University of Alabama at Birmingham
October 1998- April 2006

Professor, Human Genetics
University of Alabama at Birmingham
October 1998-April 2006

Director, Medical Genetics Residency Program,
University of Alabama at Birmingham,
2000 – 2003

Medical Director, Reproductive Genetics Screening
& Diagnostic Laboratory
University of Alabama at Birmingham
August 1994- April 2006

Associate Professor
Division of Maternal-Fetal Medicine
University of Alabama at Birmingham
August 1994 - Sept. 1998

Assistant Professor
Division of Maternal-Fetal Medicine
University of Alabama at Birmingham
August 1992 - July 1994

Assistant Professor
Division of Maternal-Fetal Medicine
Acting Director of Prenatal Diagnosis
University of Iowa Hospitals and Clinics
July 1, 1990 - June 30, 1992

EDUCATION:

Case Western Reserve University
Cleveland, OH 09/1972 – 06/1976
B.A. Biology, Cum Laude, 1976

Case Western Reserve University School of Medicine
Graduate School (PhD Program), Department of Pathology
Cleveland, OH 09/1976 – 06/1977

Columbia University Graduate School of Arts and Sciences
Graduate School (PhD Program), Pathology
New York City, NY 09/1977 – 06/1979
M.A. Pathology, 1979

Case Western Reserve University School of Medicine
Cleveland, OH 09/1979 - 05/1983
M.D., 1983

Brown University, Providence, RI,
M.A. (ad eundem) , 2010

RESIDENCY:

University of Illinois Hospital
Department of Obstetrics and Gynecology
Chicago, IL 07/1983 - 06/1987
W.N. Spellacy, M.D., Chairman

FELLOWSHIPS:

University of Illinois Hospital
Department of Obstetrics and Gynecology
Division of Maternal Fetal Medicine
Chicago, IL 07/1987 - 06/1989
S.A. Gall, M.D., Program Director

University of Iowa Hospital
Division of Medical Genetics
Iowa City, IA 07/1988 - 06/1990
J. W. Hanson, M.D., Program Director

**BOARD
CERTIFICATION:**

Diplomat of the American Board of Medical Genetics, 1990 (lifetime)

Diplomat of the American Board of Obstetrics and Gynecology, 1992;
Recertified annually through present

Diplomat of American Board of Obstetrics and Gynecology,
Subspecialty Maternal-Fetal Medicine, 1994
Recertified annually through present

LICENSURE:

Rhode Island License # 13064
Massachusetts License # 242104
Connecticut License # 049169 (inactive)
Alabama License #16316 (inactive)
Tennessee License # MD 0000041656 (inactive)

**RECENT
HOSPITAL
APPOINTMENTS:**

Women and Infants Hospital of Rhode Island
Medical Staff, July 2009 to July 2018
Director, Division of MFM, 2009 to 2018

Southcoast Hospitals Group (St. Lukes Hospital, New Bedford, MA;
Charlton Hospital, Fall River, MA; Tobey Hospital, Warham, MA)
Medical staff, 2010 to 2018
Director, MFM Services, 2010 to 2018
Director, Obstetric Executive Committee, 2010 to 2013

Backus Hospital, Norwich CT
Medical Staff, 2010 to 2017

Memorial Hospital of Rhode Island, Pawtucket, RI
Medical Staff, 2013 to 2017

MEMBERSHIPS:

American Gynecologic and Obstetric Society, 2001- present
American College of Obstetrics and Gynecology – Fellow
Society for Gynecologic Investigation -- Regular Member
Society of Maternal-Fetal Medicine -- Regular Member
American Society of Human Genetics
American Institute of Ultrasound in Medicine
Teratology Society
Alpha Omega Alpha

**AWARDS,
HONORS:**

Society for Gynecologic Investigation President's Achievement Award,
2001

Society for Maternal-Fetal Medicine, Genetics Oral Presentation Award,
January, 1999:

Wenstrom KD, Owen J, Chu DC, Boots L.

"Prospective evaluation of free beta hCG and dimeric inhibin A for
aneuploidy detection." Society of Maternal-Fetal Medicine, San
Francisco, CA, January 1999

Society for Perinatal Obstetrics, Genetics Oral Presentation Award,
January 1997:

Wenstrom KD, Owen J, Chu DC, Boots L.

"Alphafetoprotein, free beta human chorionic gonadotrophin, and
dimeric inhibin A produce the best results in a three-analyte multiple
marker screening test for fetal Down syndrome". Society of
Perinatal Obstetricians, Anaheim, CA, January 1997.

ACOG Annual Meeting First Prize for best scientific paper, 1995:

Chapman SJ, Brumfield CG, Wenstrom KD, DuBard MB

"Pregnancy Outcomes Following False Positive Multiple Marker
Screening Tests."

Society for Perinatal Obstetricians Poster Award, 1995:

Wenstrom KD, Weiner C, Merrill D, Neibyl J.

A placebo-controlled trial of the terbutaline pump for prevention of
preterm delivery. Society of Perinatal Obstetricians, Atlanta, GA,
Jan 1995

Society for Perinatal Obstetricians Poster Award, 1995:

Wenstrom KD, Hauth J, Goldenberg RL, DuBard M, Lea C.

The effect of low-dose aspirin on the development of preeclampsia in
women with elevated hCG. Society of Perinatal Obstetricians, Atlanta,
GA, January 1995.

“Outstanding Reviewer” (Top 5%) for the American Journal of Obstetrics and Gynecology, 2003, 2004, 2005

“Outstanding Reviewer” (Top 10%) for Obstetrics and Gynecology, 2001 to present

Academic Keys Who's Who in Medical Sciences Education, 2005- present

Elected to "Best Doctors in America®" annually from 2001 to present

Elected to “The Best Doctors for Women” annually from 2001 to present

Good Housekeeping's "Best Doctors for Women" - August 1997

Listed in “Guide To America’s Top Physicians”, 2004 to present

Listed in “America’s Top Obstetricians and Gynecologists” (Consumer’s Research Council of America), 2011

Listed in American Men and Women of Science, 2013- -present

Resident Medical Education Excellence in Teaching Award,
Brown Alpert Medical School, 2010, 2011, 2012, 2013, 2017, 2018

Resident Top Hospital-Based Faculty Teacher of the Year, 2011-2015

Undergraduate Hospital Based Faculty Excellence in Teaching Award,
2016

Chief Resident Excellence in Teaching Award 2013

GRANT REVIEW:

March of Dimes Committee A (Grant Review) ; 2001, 2002

NIH Obstetrics and Maternal-Fetal Biology Subcommittee, 2002-2007
Chairman, 2006-2007

Food and Drug Administration /Office of Orphan Products Grant Review
Panel, May 2018

Food and Drug Administration /Office of Orphan Products Grant Review
Panel, December , 2018

EDITORIAL BOARDS:

American Journal of Perinatology, 2001 to 2010

American Journal of Obstetrics and Gynecology, Advisory Board for
Subspecialty Areas (Genetics and Teratology) 2002 to present

JOURNAL EDITOR: Obstetrical and Gynecological Survey,
Editor -in-Chief for Obstetrics, July 2005 to March 2011

BOARD OF DIRECTORS: Society for Maternal-Fetal Medicine, 1998 to 2009
Immediate Past President 2008-2009
President- 2007-2008
President-Elect, 2006-2007
Secretary Treasurer, 2004 to 2006
Assistant Secretary Treasurer, 2001-2004
Board Member 1998-2000

American College of Obstetricians and Gynecologists (ACOG)
Executive Board of Directors, 2007-2009

PROFESSIONAL SERVICE: American College of Obstetricians and Gynecologists (ACOG)
Committee Memberships:
CREOG Exam, 1999-2000
Genetics (SMFM Representative), 1998-2000
Obstetric Practice (SMFM Representative), 1998 to 2005
Obstetric Bulletins, 2001-2004

ACOG Postgraduate Courses:
Controversies in Obstetrics. Speaker, February, 1996
Antepartum and Intrapartum Fetal Assessment. Speaker,
December 1997
Medical Complications of Pregnancy. Course Director, July 1998
Controversies in Obstetrics. Speaker, December 1999
Medical Complications of Pregnancy. Course Director, February
2001
Controversies in Obstetrics. Speaker, February, 2002
Controversies in Obstetrics. Speaker, December, 2003
Controversies in Obstetrics. Speaker, September, 2004
Management of Multiple Gestation, Course Director, May, 2006.
Noninvasive Prenatal Testing, Speaker, May, 2015

Precis Editorial Task Force, 2003- 2005

Society for Maternal Fetal Medicine:
Member, Board of Directors, 1998 to 2009 (see above)
Chairman, Publication Committee, 2003 to 2007
Member, Finance Committee, 2001 - 2006

Postgraduate Course Participation:
Genetics. *Speaker* – SMFM Meeting , 1998
Genetics. Course Director - SMFM Meeting, 2004

Genetics. *Speaker* - SMFM Meeting, 2006
Genetics. *Course Director* - SMFM Meeting, 2009
Putting the "M" Back in MFM - SMFM meeting, 2017

Masters Series Lectures:

SMFM Meeting, 1999
SMFM Meeting 2000
SMFM Meeting, 2006
SMFM Meeting, 2007

MFM Fellows Lectures

Fellows Retreat –Speaker. October 1997
Fellows Retreat –Speaker. October 1999
Annual Fellows Talk—Invited Speaker, SMFM Meeting, 2003

American Gynecologic and Obstetric Society:

Fellowship Committee, 2001-2003
Program Advisory Committee, 2004-2007

State of Rhode Island

Prematurity Prevention Task Force, Chairman 2013- 2018

BOARD EXAMINER:

Maternal Fetal Medicine, 1996 - 2000
General Obstetrics & Gynecology, 1997 – 2001

**INVITED
PARTICIPATION
IN NATIONAL
WORKSHOPS:**

Food and Drug Administration / Cellular, Tissue, and Gene Therapies
Advisory Committee Panel Member, February 2014

NICHD, SMFM, and ACOG Workshop on “Prevention of the First
Cesarean” (Presenter, Co-Author of Summary), February, 2012

NICHD Workshop on Preconception Care, Invited Participant
(Speaker), April, 20

Food and Drug Administration / NIH Health Advisory Committee
on Reproductive Drug Products, Panel Member, August,
2006 (17 α - hydroxyprogesterone caproate)

NICHD Prenatal Screening Workshop, Invited Participant
(Speaker), December, 2005

NICHD Workshop on the Border of Viability, Invited Participant
(Speaker), March, 2004

Food and Drug Administration / NIH Health Advisory Committee on Reproductive Drug Products, Panel Member, December, 2003 (OCPs with folic acid)

Food and Drug Administration / NIH Conference on Drugs in Pregnancy, Panel Member, December 2000

NIH Recombinant DNA Advisory Committee; Gene Therapy Policy Conference: "Prenatal Gene Transfer: Scientific, Medical, and Ethical Issues", Invited Participant (Speaker), January, 1999

NIH Workshop, Pharmacodynamic Differences Between Men and Women, Invited Participant (Speaker), May 1999

CDC Workshop on State-Based Birth Defects Surveillance, Invited Participant (Speaker), September 1992

**PEER JOURNAL
REVIEWER:**

New England Journal of Medicine
British Journal of Obstetrics and Gynecology
Obstetrics and Gynecology
American Journal of Obstetrics and Gynecology
Gynecologic and Obstetric Investigation
International Journal of Gynecology and Obstetrics
Reproductive Medicine
Birth Defects Research
American Journal of Perinatology
Journal of Maternal-Fetal Medicine
Obstetric Medicine
Expert Review of Cardiovascular Therapy
Life Sciences
Journal of Developmental Origins of Health and Disease
International Journal of Gynecologic Cancer
Society for Maternal Fetal Medicine (Abstracts)
Society for Gynecologic Investigation (Abstracts)
The Application of Clinical Genetics

GRANTS/FUNDING:

National Institutes of Health 1 R03 HD4158-01: Primary Investigator
"The Molecular Genetic Basis of Cardiac Defects"
\$100,000 (1/2001-1/2003)

UAB Health Services Foundation General Endowment Fund, Primary Investigator; "First Trimester Down Syndrome Screening and Diagnosis" \$ 259,500. 1/2003-1/2005

Low Birthweight PORT: Investigator
 Agency for Health Care Policy & Research Contract #290-92-0055
 U.S. Dept. Of Health & Human Services, Public Health Service

**ACADEMIC
 COMMITTEES:**

University of Alabama:

Obstetrics and Gynecology Promotions Committee, 2004 -2006
 Resident Education Committee, 1998 –2006
 Obstetrics & Gynecology Conference Committee 1994-2000
 Perinatal Morbidity and Mortality Committee, 1992 - 2002
 Kirklin Clinic Practice Committee 1994-1998
 Genetics Search Committee 1996-1997
 Hospital Executive Director Search Committee 1998-1999
 Genetics Search Committee 1998 - 2000
 Psychiatry Search Committee 2000 – 2002

Women and Infants Hospital of Rhode Island:

Ob Gyne Executive Committee, 2009 to 2018
 Ob Gyne Promotions Committee, 2009- 2018
 Resident Review Committee, 2009 to 2018
 Ob Gyne Practice Guidelines Committee, 2009 to 2018
 Chairman, 2013- 2018
 Quality Council, 2009 to 2018
 Utilization Review Committee, 2009 to 2014
 WIH Ambulatory EMR Steering Committee, 2009 to 2017
 Genetics Search Committee, 2011-2012; 2014- 2015
 Ambulatory Division Director Search Committee 2012- 2014
 CNE Obsetrics Working Group, 2013- 2017
 BC/BS Maternity Bundle Working Group, 2013- 2015
 Chair of Medicine Search Committee, 2013- 2015
 Repro-Endocrinology Division Director Search Committee, 2013-2015
 Professional Revenue Cycle Committee, 2014-2017 (Chair, 2015- 17)
 Maternal Fetal Medicine Academic Search Committee (Chair), 2015- 17
 Labor and Delivery Planning Committee, 2015- 2017

Brown Alpert Medical School

Committee on Medical Faculty Appointments, 2015- present

TEACHING:

Director, Medical Genetics Residency Program (UAB), 2000-2003
 Clinical & Research Mentor, Combined Maternal-Fetal Medicine/Genetics
 Fellowship (UAB) , 2000 - 2006
 Tutorial in Genetics (UAB), MFM Fellows, every other year, 1993 - 2006
 Clinical and Research Mentor, MFM Fellowship, 1992 - present
 Lecturer, Reproductive Genetics, 2nd Year Med.School (UAB), 1994 –
 2006

Lecturer, Ob-Gyne, 3rd Year Med. School (UAB), 1992 - 2006
 Lecturer, Masters Program, Maternal and Child Health (UAB), 1996 –
 2005
 Tutorial in Genetics (WIH), MFM and REI Fellows, 2015, 2017

TEXTBOOKS: Co-Author, Williams Obstetrics, 21st Edition, McGraw-Hill Inc, May 2001;
 Co-Author, Williams Obstetrics, 22nd Edition, McGraw-Hill Inc, March, 2005

PEER REVIEWED PUBLICATIONS

1. Wenstrom KD, Gall SA: Incidence, morbidity and mortality, and diagnosis of twin gestations. Clin Perinatol 1988; 15:(1), 1 -11.
2. Wenstrom KD, Parsons MT: The prevention of meconium aspiration in labor using amnioinfusion. Obstet Gynecol 1989;73:(4), 647-651.
3. Wenstrom KD, Gall SA: HIV Infection in Pregnancy. Obstet Gynecol Clin NA 1989;16:627-641.
4. Wenstrom KD, Williamson RA, Hoover, WW, Grant SS: Achondrogenesis type II (Langer Saldino) in association with jugular lymphatic obstructive sequence. Prenat Diagn 1989;9:527-532.
5. Wenstrom KD, Zuidema LJ: Determination of the seroprevalence of human immunodeficiency virus infection in gravidas by non-anonymous vs anonymous testing. Obstet Gynecol 1989;74:558-561.
6. Weiner CP, Grant SS, Hudson J, Williamson RA, Wenstrom KD: Effect of diagnostic and therapeutic cordocentesis upon maternal serum alpha fetoprotein concentration. Am J Obstet Gynecol 1989;161:706-708.
7. Weiner CP, Heilskov J, Pelzer GD, Grant SS, Wenstrom KD, Williamson RA: Normal values for human umbilical venous and amniotic fluid pressures and their alteration by fetal disease. Am J Obstet Gynecol 1989; 161:714-717.
8. Weiner CP, Pelzer GD, Heilskov J, Wenstrom KD, Williamson RA: The effect of intravascular transfusion on umbilical venous pressure in anemic fetuses with and without hydrops. Am J Obstet Gynecol 1989; 161:1498-1501.
9. Wenstrom KD, Weiner CP, Williamson RA, Grant SS: Prenatal diagnosis of fetal hyperthyroidism using cordocentesis. Obstet Gynecol 1990;75:1-5.

10. Pollack KL, Chestnut DH, Wenstrom KD: Anesthetic management of a parturient with Eisenmenger's syndrome. Anesth Analg 1990;70:212-215.
11. Wenstrom KD, Weiner CP, Williamson RA: Diverse maternal and fetal pathology associated with absent diastolic flow in the umbilical artery of high risk fetuses. Obstet Gynecol 1991;77:374-378.
12. Wenstrom KD, Muilenberg AC, Patil SR, Hanson JW: A unique phenotype associated with a pericentric inversion of chromosome 6 in three generations. Am J Med Genet 199;39:102-105
Note: This entity is listed as "Wenstrom Syndrome" in the London Dysmorphology Database.
13. Dragich DS, Ross AF, Chestnut DH, Wenstrom KD: Respiratory failure during amniofusion for thick meconium during labor. Anesth Analg 1991;72:549-551.
14. Wenstrom KD, Williamson RA, Weiner CP, Sipes SL, Yuh WTC: Magnetic resonance imaging of fetuses with intracranial defects. Obstet Gynecol 1991;77:529-532.
15. Wenstrom KD, Weiner CP, Hanson JW: A five year state wide experience with congenital diaphragmatic hernia. Am J Obstet Gynecol 1991; 165:838-841.
16. Sipes SL, -Weiner CP, Wenstrom KQ, Williamson RA, Grant SS: The association between fetal karyotype and mean corpuscular volume. Am J Obstet Gynecol 1991;165:1371-1376.
17. Weiner CP, Williamson RA, Wenstrom KD, Sipes SL, Grant SS, Widness J: Management of fetal hemolytic disease by cordocentesis: 1. Prediction of fetal anemia. Am J Obstet Gynecol 1991;165:546-553.
18. Weiner CP, Williamson RA, Wenstrom KD, Sipes SL, Widness JA, Grant SS, Estle C: Management of fetal hemolytic disease by cordocentesis: ii-Outcome of treatment. Am J Obstet Gynecol 1991;165:1302-1307.
19. Weiner CP, Wenstrom KD, Sipes SL, Williamson RA: Risk factors for cordocentesis and intravascular transfusions. Am J Obstet Gynecol 165:1021-1025, 1991.
20. Weiner CP, Sipes SL, Wenstrom KD: The effect of gestation upon normal fetal laboratory parameters and venous pressure. Obstet Gynecol 1992;79:713-718.
21. Wenstrom KD: Pulmonary hypoplasia and deformations related to premature rupture of membranes. Obstet Gynecol Clin NA, Wenstrom KD, Weiner CP, Editors 1992;19(2):397-408.
22. Wenstrom KD, Tessen JA, Zlatnik FJ: Frequency, distribution, and theoretical mechanisms for hematologic and weight discordance in monozygotic twins. Obstet Gynecol 1992;80:257-261.
23. Wenstrom KD, Weiner CP, Williamson RA: Antenatal Treatment of Fetal Alloimmune Thrombocytopenia. Obstet Gynecol 1992;80:433-5

24. Wenstrom KD, Sipes SL, Williamson RA, Grant SS, Trawick DC, Estle LC. Prediction of pregnancy outcome with single versus serial MSAFP tests. Am J Obstet Gynecol 1992;167:1529-33.
25. Wenstrom KD. Midtrimester selective delivery of an acardiac twin (Letter). Am J Obstet Gynecol 1993;168:1647.
26. Wenstrom KD, Syrop CH, Hammitt DG, Van Voorhis BJ: Increased risk of monozygotic twinning associated with assisted reproduction. Fertil Steril 1993;60:510-4.
27. Wenstrom KD, Williamson RA, Grant SS, Hudson JD, Getchell JP: Evaluation of Multiple Marker Screening for Down Syndrome in a State-Wide Population. Am J Obstet Gynecol 1993; 169:793-7.
28. Sipes SL, Weiner CID, Wenstrom KD, Williamson RA, Grant SS: Fetal echogenic bowel on ultrasound: Is there clinical significance? Fetal Diag Therapy 1994;9:38-43.
29. Wenstrom KD, Williamson RA, Grant SS. Detection of fetal Turner syndrome with the expanded MSAFP screen. Am J Obstet Gynecol 1994; 170:570-3.
30. Maher JE, Wenstrom KD, Hauth JC, Meis PJ. Amniotic fluid embolism after saline amnioinfusion: two cases and review of the literature. Obstet Gynecol 1994;83:851-4.
31. Weiner CP, Wenstrom KD. Outcome of alloimmunized fetuses managed solely by cordocentesis but not requiring antenatal transfusion. Fetal Diag Therapy 1994;9:233-38.
32. Wenstrom KD, Owen J, Boots LR, DuBard MB. Elevated second trimester hCG in association with poor pregnancy outcome. Am J Obstet Gynecol 1994;171:1038-41.
33. Owen J, Wenstrom KD, Hardin JM, Boots LR, Hsu CC, Cospers P, DuBard M. The utility of fetal biometry as an adjunct to the multiple marker screening test for Down syndrome. Am J Obstet Gynecol 1994; 171:1041-6.
34. Weiner CP, Estle LC, Wenstrom KD: Management of fetal hemolytic disease by cordocentesis: iii. Outcome of affected neonates not requiring antenatal transfusion. Fetal Diagnosis and Therapy 1994;9:233-8.
35. Berdahl LID, Wenstrom KD, Hanson JW. Web neck anomaly and its association with congenital heart disease. Am J Med Genetics 1995;56:304-7.
36. Brumfield CG, Davis RO, Owen J, Wenstrom KD, Boots L, DuBard MA. Will alpha-fetoprotein analysis be useful in detecting fetal anomalies in the first trimester.? J Mat Fet Med 1995;4:257-61.
37. Wenstrom KD, Hauth JC, Goldenberg RL, DuBard M, Lea C. The effect of low-dose aspirin on the development of preeclampsia in women with elevated hCG. Am J Obstet & Gynecol 1995;173:1292-6.

38. Wenstrom KD, Owen J, Boots L, Ethier M. The influence of maternal weight on hCG in the multiple marker screening test. Am J Obstet & Gynecol 1995; 173:1297-300.
39. Wenstrom KD, Desai R, Owen J, DuBard M, Boots L. Comparison of multiple marker screening with elective amniocentesis for detection of aneuploidy in women. 35. Am J Obstet & Gynecol 1995;173:1287-92
40. Brumfield CG, Wenstrom KD, Boots LR, DuBard MB, Finley SB, Davis RO. Does the multiple marker screening test identify chromosome abnormalities in the first trimester? J Mat Fet Med 1995;4:272-6.
41. Wenstrom KD, Andrews WW, Maher JE. Amnioinfusion survey: Prevalence, protocols, and complications. Obstet Gynecol 1995;86:572-6.
42. Alexander JM, Wenstrom KD, Johnson WH. Increased stroke volume in fetuses with heartblock. J Mat Fet Med 1995;4:277-9
43. Wenstrom KD, Owen J, Davis RO, Brumfield CG. The prognostic value of unexplained elevated amniotic fluid alphafetoprotein. Obstet Gynecol 1996;87:213-6.
44. Wenstrom KD, Boots L, Cospers P. The multiple marker screening test: identification of fetal cystic hygroma, hydrops, and sex chromosome aneuploidy. J Mat Fet Med 1996;5:31-5.
45. Brumfield CG, Guinn DA, Davis RO, Owen J, Wenstrom KD, Mize P. The significance of nonvisualization of the fetal bladder during an ultrasound examination to evaluate second trimester oligohydramnios. Ultrasound Obstet Gynecol 1996;8:186-91.
46. Wenstrom KD, Andrews WW, Tamura T, DuBard M, Johnston KE, Hemstreet GP. Elevated amniotic fluid interleukin-6 levels at genetic amniocentesis predict subsequent pregnancy loss. Am J Obstet Gynecol 1996; 175:830-3.
47. Wenstrom KD, Owen J, Boots L. The effect of parity correction on Down syndrome detection using the Multiple Marker Screening Test. Am J Obstet Gynecol 1996; 175:1004-7.
48. Wenstrom KD, LD Berhdahl, JW Hanson. Web neck anomaly and its association with congenital heart disease. (Letter to the editor) Am J Med Genet 1996;64:606.
49. Brumfield CG, Wenstrom KD, Davis RO, Owen J, Cospers P. Second trimester cystic hygroma--Prognosis of septated versus nonseptated lesions. Obstet Gynecol 1996;88:979-82.
50. Wenstrom KD. Understanding How Neural Tube Defects Occur -- They can be prevented. Medscape On-line Services, SCP Communications, New York, NY, December 1996.
51. Wenstrom KD, Owen J, Boots, L. Second trimester maternal serum CA-1 25 is superior to estriol in the multiple marker screening test for Down syndrome. Obstet Gynecol 1997;89:1-5.

52. Wenstrom KD, Owen J. Maternal serum human chorionic gonadotrophin level at 15 weeks (Letter to the Editor) Am J Obstet Gynecol 1997; 176:258.
53. Wenstrom KD, Weiner C, Merrill D, Neibyl J. A placebo-controlled trial of the terbutaline pump for prevention of preterm delivery. Am J Perinat 1997;14:87-91.
54. Chapman SJ, Burmfield CG, Wenstrom KD, DuBard MB. Pregnancy outcomes following false positive multiple marker screening tests. Am J Perinatol 1997;14:475-8.
55. Wenstrom KD, Owen J, Chu DC, Boots L. Free beta hCG subunit versus intact hCG in the multiple marker screening test for fetal Down syndrome. Obstet Gynecol 1997;90:370-4.
56. Wenstrom KD, Owen J, Chu DC, Boots L. Alphafetoprotein, free beta human chorionic gonadotrophin, and dimeric inhibin A produce the best results in a three-analyte multiple marker screening test for fetal Down syndrome. Am J Obstet Gynecol 1997;177:987-991.
57. Wenstrom KD, Owen J, Chu DC, Boots L. Elevated second trimester dimeric inhibin A levels identify Down syndrome pregnancies. Am J Obstet Gynecol 1997; 177:992-997.
58. Wenstrom KD, Owen J, Brumfield CG, Davis RO, DuBard M, Garcia T. Significance of a false positive trisomy 18 multiple marker screening test. Obstet Gynecol 1997;90:938-42.
59. Rouse DJ, Goldenberg RL, Wenstrom KD. Antenatal screening for Factor V Leiden mutation: A critical appraisal. Obstet Gynecol, 1997;90:848-51.
60. Wenstrom KD, Owen J, Brumfield CG, Davis RO, DuBard M. Significance of a false positive trisomy 18 multiple marker screening test. (Letter to the Editor) Obstet Gynecol 1997;90:938-42.
61. Chu DC, Hsu C, Wenstrom KD, Boots LR. Insulin-like growth factor binding protein -3 (IGFB-3) in prenatal detection of fetal Down syndrome pregnancies Obstet Gynecol 1998; 91: 192-5
62. Wenstrom KD, Andrews WW, Hauth JC, Goldenberg RL, DuBard M, Cliver S. Elevated second trimester amniotic fluid interleukin-6 levels predict preterm delivery. Am J Obstet Gynecol 1998;178:546-50.
63. Brumfield CG, Davis RO, Owen J, Wenstrom KD, Kynerd PM. Pregnancy outcomes following sonographic nonvisualization of the fetal stomach. Obstet Gynecol 1998;91:905-8.
64. Wenstrom KD, Andrews WW, Bowles N, Towbin JA, Hauth JC, Goldenberg RL. Intrauterine viral infection at the time of second trimester genetic amniocentesis is not associated with post-procedure pregnancy loss Obstet Gynecol 1998;92:420-4.
65. Guinn DA, Goepfert AR, Owen J, Wenstrom KD, Hauth JC. Terbutaline pump maintenance therapy for prevention of preterm delivery: A double blind trial. Am J Obstet Gynecol 1998; 179:874-8.

66. Wenstrom KD, Chu DC, Owen J. MSAFP, free PhCG, and dimeric inhibin A detect aneuploidies other than Down Syndrome. Am J Obstet Gynecol 1998; 179:966-70.
67. Biggio JR, Wenstrom KD, DuBard M. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol. 1999; Nov;94(5 Pt 1):773-7.
68. Faye-Petersen OM, Guinn DA, Wenstrom KD. The value of perinatal autopsy. Obstet Gynecol 1999;96:915-20.
69. Wenstrom KD, Descartes M, Franklin J, Cliver SP. A five year experience with Fragile X screening of high risk gravidas. Am J Obstet Gynecol 1999;181:789-92.
70. Wenstrom KD, Owen J, Chu DC, Boots L. Prospective evaluation of free BhCG and dimeric inhibin A for aneuploidy detection. Am J Obstet Gynecol 1999;181:887-92.
71. Guinn DA, Goepfert AR, Owen J, Wenstrom KD, Hauth JC. Reply-Letter to the Editor, re: Terbutaline pump maintenance therapy for prevention of preterm delivery: A double blind trial. Am J Obstet Gynecol 1999; 180:1593-4.
72. HS, Canick A Kellner LH for the Collaborative Study Group. Collaborative Study of Maternal Urine. Core human chorionic gonadotrophin screening for Down syndrome. Prenat Diag 1999;19:911-7.
73. Johanning G, Wenstrom KD, Johnston KE, Tamura T. The risk of neural tube defects and the combination of methionine synthase and 5,10-methylene tetrahydrofolate reductase polymorphisms. FASEB J 1999;13: A229
74. Wenstrom KD, Johanning G, Owen J, Johnston KE, Acton S, Tamura T. The relationship of amniotic fluid homocysteine levels, fetal methylenetetrahydrofolate reductase genotypes, and neural tube defects. Am J Med Genet. 2000; Jan 3,90(I):12-6.
75. Wenstrom KD, Johanning G, Owen J, Johnston KE, Acton S, Tamura T. Amniotic fluid homocysteine levels, methylenetetrahydrofolate reductase genotypes, and neural tube closure sites. Am J Med Genet 2000; Jan 3,90(I):6-11.
76. Brumfield CG, Wenstrom KD, Owen J, Davis RO. Ultrasound findings and Multiple Marker Screening in Trisomy 18. Obstet Gynecol 2000;95:51-4.
77. Johanning G, Tamura T, Johnston KE, Wenstrom KD, Comorbidity of 5,10 methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms and risk for neural tube defects. J Med Genet 2000; 37:949-51.
78. Wenstrom KD, Johanning GL, Johnston KE, DuBard M. The methylenetetrahydrofolate reductase 677C-->T mutation and elevated homocysteine levels are associated with congenital cardiac malformations. Am J Obstet Gynecol 2001; 184:806-17.

79. Biggio JR, Owen J, Wenstrom KD, Oakes WJ. Can prenatal ultrasound findings predict ambulatory status in fetuses with open spina bifida (OSB)? Am J Obstet Gynecol 2001;185:1016-20.
80. Biggio JR, Owen J, Wenstrom KD. Predicting ambulation by checking leg withdrawal in fetuses with spina bifida. Am J Obstet Gynecol 2002;187:256.
81. Biggio JR, Wenstrom KD. Biochemical screening for fetal aneuploidy. Infertil and Reprod Med Clin North Amer, 2002.
82. Johanning G, Wenstrom KD, Tamura T. Changes in frequencies of heterozygous thermolabile 5,10-methylenetetrahydrofolate reductase in fetuses with neural tube defects. Am J Med Genet 2002;39:366-367.
83. Wenstrom KD. Fragile X and other trinucleotide repeat diseases. Obstet Gynecol Clin N Am 2002;29:367-88.
84. Ramsey PS, Andrews WW, Goldenberg RL, Tamura T, Wenstrom KD, Johnston KE. Elevated amniotic fluid ferritin levels are associated with inflammation-related pregnancy loss following mid-trimester amniocentesis. J Mat Fet Med 2002;11:302-306.
85. Wenstrom KD. Aneuploidy Screening: The Changing Scene. Obstetrics and Gynecology, 2003; 101:840-842
86. Wenstrom KD. Fetal Surgery for Congenital Diaphragmatic Hernia. N.Engl J Med 2003; 349; 20: 1887-8
87. Biggio JR, Wenstrom KD, Owen J. Fetal open spina bifida: a natural history of disease progression in utero. Prenatal Diagnosis 2004; 24:287-9
88. Biggio J, Ramsey PS, Cliver SP, Lyons MD, Goldenberg RL, Wenstrom KD. Midtrimester amniotic fluid metalloproteinase-8 (MMP-8) levels above the 90th percentile are a marker for subsequent preterm premature rupture of the membranes. Am J Obstet Gynecol 2005; 192: 109-13
89. Wenstrom KD. First trimester Down syndrome screening: component analytes and timing for optimal performance. Semin Perinat 2005; 29: 195-202
90. Wenstrom KD. Evaluation of Down syndrome screening strategies. Semin Perinat 2005; 29: 219-224
91. Lu G, Owen J, Wenstrom KD. Obstetrics and gynecology resident attitudes toward maternal-fetal medicine fellowship training. J Mat Fet Neon Med 2004; 16(5): 259-63.
92. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G, Wenstrom KD, Samuels P, Cotroneo MA, Moawad A, Sorokin Y, Meis P, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ, Gabbe SG, for the National Institute of Child Health and Human Development

Maternal–Fetal Medicine Units Network . The Relationship of the Factor V Leiden Mutation and Pregnancy Outcomes for Mother and Fetus. Obstet Gynecol, 2005; 106: 517-524

93. Aagaard-Tillery K, Sibai B, Spong CY, Momirova V, Wendel G, Wenstrom K, Samuels P, Cotroneo M, Moawad A, Sorokin Y, Miodovnik M, Meis P, O'Sullivan MJ, Conway D, Wapner RJ. National Institutes of Child Health and Human Development Maternal Fetal Medicine Units Network. Sample bias among women with retained DNA samples for future genetic studies. Obstet Gynecol, 2006; 108(5): 115-20
94. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K, Samuels P, Caritis SN, Sorokin Y, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (NICHD MFMU) Network. Prothrombin gene G20210A mutation and obstetric complications Obstet Gynecol, 2010 Jan;115(1):14-20.
95. Rogers BB, Momirova V, Dizon-Townson DS, Wenstrom K, Samuels P, Sabai BM, Spong CY, Caritis SN, Sorokin Y, Miodovnik M, O'Sullivan MJ, Conway DL, Wapner RJ. Avascular villi, increased syncytial knots, and hypervascular villi are associated with pregnancies complicated by Factor V Leiden mutation Pediatr Dev Pathol, 2010 Feb 1. [Epub ahead of print] PMID: 20121426.
96. Aagaard-Tillery K, Spong CY, Thom E, Sibai B, Wendel G Jr, Wenstrom K, Samuels P, Simhan H, Sorokin Y, Miodovnik M, Meis P, O'Sullivan MJ, Conway D, Wapner RJ; Eunice Kennedy Shriver National Institute of Child Health, Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). Pharmacogenetics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes. Obstet Gynecol, 2010 Mar;115(3):568-77.
97. Horton AL, Momirova V, Dizon-Townson D, Wenstrom K, Wendel G, Samuels P, Sibai B, Spong CY, Cotroneo M, Sorokin Y, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network (MFMU). Family history of venous thromboembolism and identifying factor V Leiden carriers during pregnancy. Obstet Gynecol, 2010 Mar;115(3):521-5.
98. Manuck T, Branch DW, Lai Y, Sibai B, Spong CY, Wendel G Jr, Wenstrom K, Samuels P, Caritis SN, Sorokin Y, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden. Journal of Reproductive Immunology, 85:180-185, 2010. PMID: 20439118.
99. Wenstrom K, Erickson K, Schulkin J. Are obstetrician-gynecologists satisfied with their MFM consultants? A Survey. Am J Perinatology , 2012; 29 (8): 599-608. [Epub ahead of print May 25, 2012]
100. Spong CY, Berghella V, Wenstrom K, Mercer BM, Saade GR. Preventing the first cesarean: Summary of a joint SMFM, NICHD, ACOG Workshop. Obstet Gynecol 2012; 120:1181-93

101. Wenstrom KD. Editorial: Microarray analysis: elegant, accurate, and expensive. *Obstet Gynecol*, 124(2, Part 1); 2014: 199-201
102. Wenstrom KD, Carr SR. Clinical Expert Series: Fetal Surgery: Principles, Indications, and Evidence. *Obstet Gynecol*, 2014;124:817-35
103. Dahlke JD, Mendez-Figueroa H, Wenstrom KD. Counseling women about the risks of cesarean delivery in future pregnancies. *The Obstetrician Gynecologist*, 2014; 16: 239-44
104. Wenstrom KD. The FDA's new advice on fish: it's complicated. *Am J Obstet Gynecol*, 2014; 211(5): 475-8
105. Dahlke JD MD, Mendez-Figueroa H, Maggio L, Albright CA, Chauhan SP, Wenstrom KD Early term versus term delivery in the management of fetal growth restriction: A comparison of two protocols . *Am J Perinatol*, 2015; 32(6): 523-30
106. Maggio L, Dahlke JD, Mendez-Figueroa H, Albright CM, Chauhan SP, Wenstrom KD. Perinatal outcomes with normal compared with elevated umbilical artery systolic-to-diastolic ratios in fetal growth restriction. *Obstet Gynecol* 2015; 125(4): 863-9
107. Wenstrom KD. Screening for Rh c Alloimmunisation at 27 Weeks': Not Yet Convinced . *Br J Obstet Gynaecol* 2016, May;123(6):964
108. Wenstrom KD, D'Alton M, O'Keefe D. Maternal Fetal Medicine Workforce Survey: Are We Ready for Regionalized Levels of Maternal Care? 2017; *Am J Perinatol*. 2018;35:1044–9.
109. D'Alton M, Friedman AM, Bernstein PS, Brown HL, Callaghan WM, Clark SL, Grobman WA, Kilpatrick SJ, O'Keefe DF, Montgomery DM, Srinivas SK, Wendel GD, Wenstrom KW, Foley MR. Putting the 'M' back in maternal-fetal medicine: A five-year report card on a collaborative effort to address maternal morbidity and mortality in the U.S. *Am J Obstet Gynecol*, 2019 Oct; 221(4):311-317
110. Wenstrom KD, Raby BA. Gene test interpretation: CFTR. *Up To Date*; Jan 30 2020

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

1. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA for the Collaborative Study Group. Collaborative Study of Biochemical Screening for Down syndrome. *N Engl J Med* 1994;330:1114-8.
2. Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. *N Engl J Med* 2011; 364: 993.

CHAPTERS AND REQUESTED ARTICLES

1. Wenstrom KD, Gall SA: Subsection C, Chapter Five: Maternal Immunology in Fetal Assessment: Physiological, Clinical, and Medicolegal Principles. Eden RA (Ed.), Appleton and Lange, Norwalk, CT. 1989.
2. Wenstrom KD, Weiner CP: Hypertensive Disorders in Pregnancy. In Conn's Current Therap 1990. WB Saunders Co., Philadelphia, PA.\
3. Wenstrom KD: Toxoplasmosis Infection in Pregnancy. Principles of Medical Therapy in Pregnancy. Gleicher N (Ed.) Second Edition, Appleton & Lange, East Norwalk, CT., 1992.
4. Wenstrom KD: Bites and Stings. Principles of Medical Therapy in Pregnancy. Gleicher N (Ed.) Second Edition, Appleton & Lange, East Norwalk, CT., 1992.
5. Wenstrom KD, Weiner CP: Diagnosis and Therapeutic Management of Fetal Disease. Principles of Medical Therapy in Pregnancy . Gleicher N (Ed.) Second Edition, Appleton & Lange, East Norwalk, CT., 1992.
6. Wenstrom KD, Williamson RA: Deafness: Reproductive counselling considerations. Contemp OB-GYN 33:25-30,1989.
7. Wenstrom KD: Epilepsy in pregnancy. Iowa Perinatal Letter IX(4), July-August, 1989.
8. Wenstrom KD: Epilepsy in pregnancy. Postgraduate Medicine IX(13) June, 1989.
9. Wenstrom KD: Intrauterine growth retardation. Iowa Perinatal Letter.
10. Wenstrom KID: Amnioinfusion. Postgraduate Medicine XI:(24) Nov, 1991.
11. Wenstrom KD: Amnioinfusion. The Iowa Perinatal Letter, 1992.
12. Wenstrom KD: Antepartum Fetal Assessment and Therapy. Obstetric Anesthesia: Principals and Practice. Chestnut D., editor; Mosby Year Book, Philadelphia, 1993.
13. Gardner M, Wenstrom KD. Maternal Adaptations to Multiple Gestation. In: Gall SA, ed. Multiple Pregnancy and Delivery. St. Louis, MO: Mosby-Year Book. In press, July 1994.
14. Wenstrom KD. Precis VI Prenatal Diagnosis of Genetic Disorders. Gilstrap, LC 111, Obstetrics section editor. American College of Obstetricians, 1997.
15. Wenstrom KD. Precis VI Teratogenic exposures. Gilstrap, LC 111, Obstetrics section editor. American College of Obstetricians, 1997.
16. Wenstrom KD: Fetal Tumors. In: High Risk Pregnancy: Management Options. 2nd edition. James DK, Steer PJ, Weiner CP, Gonik B, eds. Philadelphia:W. B. Saunders, 1999.

17. Wenstrom KD, Malee M. Medical and Surgical Problems in Pregnancy. In: Danforth's Obstetrics and Gynecology, 8th Edition. Scott J, DiSaia PJ, Hammond CB, Spellacy WN, eds. Philadelphia:Lippincott-Raven, 1999.
18. Wenstrom KD. The Pharmacologic Challenge of Treating Epilepsy During Pregnancy. NIH Conference: Biologic and Molecular Mechanisms for Sex Differences in Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics, 2000.
19. Wenstrom KD. ACOG Practice Bulletin, Number 27, May 2001. "Detection of Fetal Chromosomal Abnormalities".
20. Wenstrom KD. Correlation of Genotype and Phenotype. NIH Third Gene Therapy Policy Conference. Prenatal Gene Transfer: Scientific Medical and Ethical Issues, 2001.
21. Biggio, JR, Wenstrom KD. Biochemical Screening for Fetal Aneuploidy. Infertility and Reproductive Medicine Clinics of North America. October 2001, Vol 12, No. 4. Pages 1-29.
22. Wenstrom KD. Preconception Counseling for Stillbirth, Internet publication for YourDoctor.com, 2000.
23. Wenstrom KD. Cystic Fibrosis: Genetic Screening and Management of Affected Mothers and Fetuses. Up-To-Date, Burton D Rose, editor, Up-To-Date Publishing, Wellesley, MA. 2001 (updated annually to present)
24. Driscoll-DA, Wenstrom KD, Williams J, III. ACOG Committee on Genetics. ACOG Technology Assessment in Obstetrics and Gynecology. Number 1, July 2002. Genetics and molecular diagnostic testing. *Obstetrics & Gynecology* 100(1):193-211, 2002.
25. Wenstrom KD: Antepartum Fetal Assessment and Therapy. Obstetric Anesthesia: Principles and Practice. Chestnut D., editor; Mosby Year Book, Philadelphia, 2004.
26. Wenstrom KD, Cordero J, Oakley G. Folic Acid- The Right Answer. ACOG Update, 2004; Volume 29.
27. Biggio J, Wenstrom KD: Fetal Tumors. In: High Risk Pregnancy: Management Options. 3rd edition. James DK, Steer PJ, Weiner CP. Gonik B, eds. Philadelphia:W. B. Saunders, 2004.
28. Wenstrom KD: Tutorial on Prenatal Genetic Screening . Encyclopedia of Genetics, Genomics, Proteomics, and Bioinformatics. John Wiley and Sons, London, 2004.
29. Wenstrom KD. Genetic Amniocentesis. Protocols in High Risk Pregnancy, 4th Edition . Queenan JT, Hobbins JC, Spong CY, editors, 2004
30. Wenstrom KD. Cardiac Disease. Protocols in High Risk Pregnancy, 4 th Edition . Queenan JT, Hobbins JC, Spong CY, editors, 2004
31. Wenstrom KD. ACOG Practice Bulletin Number 56, October, 2004. "Multiple Gestation: Complicated Twin, Triplet, and High-Order Multifetal Pregnancy."

32. Wenstrom KD. Precis XIII Prenatal Diagnosis of Genetic Disorders. Gilstrap, LC 111, Obstetrics section editor. American College of Obstetricians, 1997.
33. Wenstrom KD. Precis XIII Teratogenic Exposures . Gilstrap, LC 111, Obstetrics section editor. American College of Obstetricians, 1997.
34. Wenstrom KD. Precis XIV Prenatal Diagnosis of Genetic Disorders. American College of Obstetricians, 2010.
35. Wenstrom KD. Precis XIV Teratogenic Exposures . American College of Obstetricians, 2010.
36. Wenstrom KD. Precis XIV Preconception Counseling. American College of Obstetricians, 2010.
37. Wenstrom KD. Precis XIV Substance Abuse. American College of Obstetricians, 2010.
38. Wenstrom KD. Genetic Amniocentesis. Protocols in High Risk Pregnancy, 5th Edition . Queenan JT, Hobbins JC, Spong CY, editors, 2010
39. Wenstrom KD. Cardiac Disease. Protocols in High Risk Pregnancy, 5th Edition . Queenan JT, Hobbins JC, Spong CY, editors, 2010
40. O'Brien BM, Wenstrom KD. Down Syndrome Screening in the First and Second Trimesters of Pregnancy. US Obstetrics and Gynecology, 2010; 4: 58-65 .
41. O'Brien BM, Wenstrom KD. Navigating Among the Options in Antenatal Screening. JWWH 2011
42. Wenstrom KD. Cardiac Disease. Protocols in High Risk Pregnancy, 6th Edition . Queenan JT, Hobbins JC, Spong CY, editors, 2015
43. Albright C, Wenstrom KD. Malignancies in pregnancy. Best Practice & Research Clinical Obstetrics & Gynecology, 2016;33:2-18. doi: 10.1016/j.bpobgyn.2015.10.004. Epub 2015 Oct 19.

****See also Obstetrical and Gynecological Survey, 5 commentaries a month from July 2005 to March 2011***

ABSTRACTS/PRESENTATIONS (ORAL PRESENTATIONS*)

1. Wenstrom KD, Parsons MT: Maternal blood urea nitrogen creatinine ratio and pregnancy outcome. The Society of Perinatal Obstetricians, Lake Buena Vista, Florida, February, 1987.

2. Wenstrom KD, Parsons MT: The prevention of meconium aspiration in labor using amnioinfusion. The Society of Perinatal Obstetricians, Las Vegas, Nevada, February, 1988.
3. Zuidema LJ, Wenstrom KD: Once a gestational diabetic, not always a gestational diabetic. The Society for Gynecologic Investigation, Baltimore, Maryland, March, 1988.
4. Wenstrom KD, Zuidema LJ: Voluntary Human Immunodeficiency Virus (HIV) Testing Does Not Accurately Identify All HIV Positive Gravidas. The Society of Perinatal Obstetricians, New Orleans, Louisiana, February, 1989.
5. Weiner CP, Grant SS, Hudson J, Williamson RA, Wenstrom KD: Effect of Diagnostic and Therapeutic Cordocentesis Upon Maternal Serum Alpha Fetoprotein (MSAFP). The Society of Perinatal Obstetricians, New Orleans, Louisiana, February, 1989.
- *6. Wenstrom KD, Williamson RA, Weiner CP, Yuh WYC: MRI of Anomalous Fetuses. International Fetal Medicine and Surgery Society, Pacific Grove, California, June, 1989.
7. Wenstrom KD, Muilenberg AC, Patil SR, Hanson JW: A unique phenotype associated with a pericentric inversion of chromosome 6 in three generations. American Society of Human Genetics, Baltimore, Maryland, November, 1989.
8. Wenstrom KD, Weiner CP, Williamson RA: The Significance of Absent Diastolic Flow in the Umbilical Artery Detected During Antepartum Evaluation of High Risk Patients. The Society of Perinatal Obstetricians, Houston, Texas, January, 1990.
9. Wenstrom KD, Weiner CP, Williamson RA: Effect of Gestational Age and Disease on Fetal Liver Function. The Society of Perinatal Obstetricians, Houston, Texas, January, 1990.
- *10. Sipes SL, Weiner CP, Wenstrom KD, Williamson RA, Grant SS: The Association Between Fetal Karyotype and Mean Corpuscular Volume. The Society of Perinatal Obstetricians, Houston, Texas, January, 1990.
- *11. Weiner CP, Wenstrom KD, Williamson RA: The Results of Direct Evaluation and Treatment of Fetal Hemolytic Disease. The Society of Perinatal Obstetricians, Houston, Texas, January, 1990.
12. Weiner CP, Hudson J, Williamson RA, Wenstrom KD, Grant SS: The Effect of Fetal Disease Upon Fetal Serum Alpha Fetal Protein (FSAFP). The Society of Perinatal Obstetricians, Houston, Texas, January, 1990.
13. Weiner CP, Williamson RA, Wenstrom KD: The Effect of Fetal Disease Upon CPK-Isoenzymes. International Society of Fetal Medicine and Surgery. New Zealand, February, 1990
14. Weiner CID, Wenstrom KD, Williamson RA: Intravascular Transfusion for the Treatment of Nonhemolytic Fetal Anemia. International Society of Fetal Medicine and Surgery, New Zealand, February, 1990.

- *15. Wenstrom KD, Williamson R, Weiner C, Yuh W: MRI of Fetuses with Intracranial Defects. Society for Gynecologic Investigation, San Diego, California, March, 1990.
- *16. Weiner CP, Williamson RA, Wenstrom KD, Grant S: Risk Factors for Complications of Cordocentesis and Intravascular Transfusion (IVT). Society for Gynecologic Investigation, St. Louis, Missouri, March, 1990.
- *17. Weiner CP, Williamson RA, Wenstrom KD, Mueller G, Grant SS, Pelzer GD, Heilskov J: Effect of Gestation Upon Hematocrit Decline After Fetal Intravascular Transfusion (IVT). Society for Gynecologic Investigation, St. Louis, Missouri, March 1990.
- 18. Sipes SL, Weiner CP, Williamson RA, Wenstrom KD: Fetal Echogenic Bowel on Ultrasound: Is There Clinical Significance? Society of Perinatal Obstetricians. San Francisco, California, January 1991.
- *19. Wenstrom KD, Weiner CID, Hanson J: A Five Year State Wide Experience with Congenital Diaphragmatic Hernia. Society of Perinatal Obstetricians, San Francisco, California, January 1991.
- 20. Wenstrom KD, Tessen A Zlatnik FJ, Weiner CP: Twin-Twin Transfusion Syndrome Cannot be Diagnosed by Discordance Alone. Society for Gynecologic Investigation, San Antonio, Texas, March 1991.
- 21. Sipes SL, Weiner CP, Wenstrom KD, Williamson RA, Grant SS: Does Abnormal Umbilical Artery (UA) Doppler Velocimetry Aid in Detection of Karyotypically Abnormal Fetuses in the Setting of Intrauterine Growth Retardation (IUGR)? Society for Gynecologic Investigation, San Antonio, Texas, March 1991.
- 22. Weiner CP, Wenstrom KD, Sipes S, Williamson R: The Fetus Treated for Hemolytic Disease: When to Deliver. Society for Gynecologic Investigation, San Antonio, Texas, March 1991.
- 23. Palomaki GE, Knight GJ, Haddow JE, Canick JA, Sailer DN, Panizza DS, Grant SS, Wenstrom KD, Hudson JD: Prospective Trial of a Screening Protocol to Identify Trisomy 18 Using Maternal Serum Alpha-Fetoprotein, Unconjugated Estriol, and Human Chorionic Gonadotropin. 8th International Congress of Human Genetics, Washington, DC, October 1991.
- 24. Engleken JD, Wenstrom KD, Weiner CP, Williamson RA: Magnetic Resonance Imaging of Fetal Abnormalities. Radiological Society of North America, Chicago, Illinois, December 1991.
- 25. Weiner CP, Estle LC, Wenstrom KD, Sipes SL: Management of fetal hemolytic disease not requiring antenatal transfusion therapy. Society of Perinatal Obstetricians, Orlando, Florida, February 1992
- 26. Wenstrom KD, Syrop CH, Hammitt DG, VanVoorhis BJ: Increased risk of monozygotic twinning associated with assisted reproduction. Society of Gynecologic Investigation, San Antonio, Texas, March 1992.

27. Wenstrom KD, Sipes SIL, Williamson RA, Grant SS, Trawick DC, Estle LC: Prediction of pregnancy outcome with single versus serial MSAFP tests. Society for Gynecologic Investigation, San Antonio, Texas, March 1992.
- *28. Wenstrom KD, Williamson RA, Grant SS: One year experience of a state-wide expanded MSAFP screening program. Society of Perinatal Obstetricians, San Francisco, California, February 1993.
29. Wenstrom KD, Patil SR, Sipes SL: Labor and delivery complications in aneuploid fetuses. Society of Perinatal Obstetricians, San Francisco, California, February 1993.
30. Wenstrom KD, Williamson RA, Grant SS: Detection of fetal Turner syndrome with the expanded MSAFP screen. Society of Perinatal Obstetricians, San Francisco, California, February 1993.
31. Alexander JM, Wenstrom KD, Johnson W. Increased stroke volume in fetuses with heartblock. Society of Perinatal Obstetricians, San Francisco, California, January 1994.
32. Wenstrom KD, Andrews WW, Maher JE. Prevalence, protocols, and complications associated with amniocentesis. Society of Perinatal Obstetricians, San Francisco, California, January 1994.
33. Wenstrom KD, Boots LR, Cospers P. Does the multiple marker screening test identify fetal sex chromosome abnormalities or just cystic hygroma/hydrops? Society of Perinatal Obstetricians, San Francisco, California, January 1994.
34. Wenstrom KD, Owen J, Boots LR, DuBard MB. Is elevated second trimester hCG associated with poor pregnancy outcome? Society of Perinatal Obstetricians, San Francisco, California, January 1994.
35. Brumfield C, Wenstrom KD, Boots LR, DuBard MB, Finley S, Davis RO. Does the multiple marker screening test identify chromosomal abnormalities in the first trimester? Society of Perinatal Obstetricians, San Francisco, California, January 1994.
36. Owen J, Wenstrom KD, Boots LR, DuBard MB, Cospers P, Hsu C. Addition of fetal biometry does not improve the multiple marker screening test for Down syndrome. Society of Perinatal Obstetricians, San Francisco, California, January 1994.
- *37. Wenstrom KD, Desai R, Owen J, DuBard M, Boots L. Comparison of multiple marker screening with elective amniocentesis for detection of aneuploidy in women. 35. Society of Perinatal Obstetricians, Atlanta, GA, January 1995.
38. Wenstrom KD, Owen J, Davis R, Brumfield C. The prognostic value of unexplained elevated amniotic fluid and maternal serum alpha-fetoprotein. Society of Perinatal Obstetricians, Atlanta, GA, January 1995.

39. Wenstrom KD, Hauth J, Goldenberg RL, DuBard M, Lea C. The effect of low-dose aspirin on the development of preeclampsia in women with elevated hCG. Society for Perinatal Obstetricians, Atlanta, GA, January 1995 (Winner, Best Poster Award).
40. Wenstrom KD, Owen J, Boots L, Ethier M. The influence of maternal weight on hCG in the multiple marker screening test. Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
41. Wenstrom KD, Weiner C, Memll D, Neibyl J. A placebo-controlled trial of the terbutaline pump for prevention of preterm delivery. Society for Perinatal Obstetricians, Atlanta, GA, January 1995 (Winner, Best Poster Award).
42. Goepfert A, Wenstrom KD, Brumfield C, Davis R, Owen J. Pregnancy outcome after the diagnosis of a fetal neural tube defect. Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
43. Berdahl LD, Wenstrom KD, Hanson JW. The relationship of web neck anomaly and congenital heart disease. Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
44. Owen J, Wenstrom KD, DuBard MB. A population-based analysis of the amniotic fluid index in 21,000 pregnancies. Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
- *45. Owen J, Wenstrom KD, Davis, RO, Brumfield CG, DuBard MB. The correlation between the amniotic fluid index and a subjective estimate of the amniotic fluid volume in 31,000 sonographic evaluations. Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
46. Guinn DA, Faye-Petersen O, DuBard MB, Wenstrom KD. How valuable is a perinatal autopsy? Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
47. Brumfield CG, Guinn DA, Davis RO, Owen J, Wenstrom KD, McBrayer P. The significance of a nonvisualized fetal bladder during an ultrasound examination to evaluate mid-trimester oligohydramnios. Society for Perinatal Obstetricians, Atlanta, GA, January 1995.
- *48. Chapman SJ, Brumfield CG, Wenstrom KD, DuBard M. Pregnancy Outcome Following False Positive Multiple Marker Screening Tests. ACOG 43rd Annual Clinical Meeting. San Francisco, Ca, May 1995.
- *49. Wenstrom KD, Andrews WW, Tamura T, DuBard M, Johnston KE, Hernstreet GP. Elevated amniotic fluid interleukin-6 levels at genetic amniocentesis predict subsequent pregnancy loss. Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.
50. Wenstrom KD, Owen J, Boots, L. The effect of parity correction on Down syndrome detection using the multiple marker screening test (MMST). Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.
51. Brumfield CG, Wenstrom KD, Davis, RO, Owen J, DuBard M, Cosper P. Early amniocentesis does not increase the risk of pregnancy loss. Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.

52. Brumfield CG, Wenstrom KD, Davis, RO, Owen J, Cospers P. Fetal cystic hygroma--prognosis of septated versus nonseptated lesions. Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.
53. Davis RO, Cospers P, DuBard M, Brumfield CG, Wenstrom KD. Spontaneous pregnancy losses in women referred for mid-trimester genetic counselling. Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.
54. Davis RO, Cospers P, DuBard M, Brumfield CG, Finley S, Owen J, Wenstrom KD. The impact of maternal serum screening tests on mid-trimester prenatal diagnosis. Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.
55. Wenstrom KD, Owen J, Boots, L. Second trimester maternal serum CA-1 25 is superior to estriol in the multiple marker screening test for Down syndrome. Society for Perinatal Obstetricians, Kona, Hawaii, February 1996.
56. Gardner M, Castellano T, Wenstrom KD, Rouse DJ, Izquierdo L, Kramer R. Cost-benefit analysis of Down syndrome screening in women less than 35 years of age. American College of Obstetricians and Gynecologists. Denver, CO, April 1996.
57. Wenstrom KD, Owen J, Chu DC, Boots L. Elevated second trimester dimeric inhibin A levels identify Down syndrome pregnancies. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
58. Wenstrom KD, Miller M, Brumfield C, Davis R, Owen J. Amniotic fluid pulmonary maturity studies may be unnecessary in fetuses with meningomyelocele and hydrocephalus. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
59. Wenstrom KD, Owen J, Brumfield CG, Davis RO, DuBard M, Garcia T. Significance of a false positive trisomy 18 multiple marker screening test. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
- *60. Wenstrom KD, Owen J, Chu DC, Boots L. Alphafetoprotein, free beta human chorionic gonadotrophin, and dimeric inhibin A produce the best results in a three-analyte multiple marker screening test for fetal Down syndrome. Society for Perinatal Obstetricians, Anaheim, CA, January 1997. (Winner, Best Oral Presentation Award)
61. Wenstrom KD, Owen J, Chu DC, Boots L. Free beta hCG subunit versus intact hCG in the multiple marker screening test for fetal Down syndrome. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
62. Brumfield CG, DuBard M, Cliver S, Owen J, Davis RO, Wenstrom KD. Sonographic measurements and ratios in fetuses with trisomy 18. Society for Perinatal Obstetricians, Anaheim, CA, January 1997
63. Brumfield CG, Davis RO, Owen J, Wenstrom KD, Mize P. Pregnancy outcomes following sonographic nonvisualization of the fetal stomach. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.

- *64. Davis RO, Brumfield CG, DuBard M, Owen J, Wenstrom KD. An assessment of fetal loss in twin pregnancy after midtrimester amniocentesis. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
65. Davis RO, Andrews WW, DuBard M, Wenstrom KD, Hauth JC. Mid-trimester interleukin-6 levels in twin pregnancies. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
66. Halcomb RT, Owen J, Georgeson KE, Wenstrom KD, Davis RO, Brumfield CG. Fetal gastroschisis: The prognostic value of antenatal sonographic findings and selected obstetric factors on neonatal outcome. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
67. Owen J, Wenstrom KD. The effect of inaccurate gestational age estimation on the multiple marker screening test (MMST) for fetal Down syndrome (DS). Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
68. Owen J, Wenstrom KD, Boots L, Hsu J, Chu DC. Optimizing the multiple marker screening test for fetal Down Syndrome using a pentavariate gaussian algorithm. Society for Perinatal Obstetricians, Anaheim, CA, January 1997.
69. Wenstrom KD, Andrews WW, Hauth JC, Goldenberg RL, DuBard M, Cliver S. Elevated second trimester amniotic fluid interleukin-6 levels predict preterm delivery. Society for Gynecologic Investigation, San Diego, CA, March 1997.
70. Wenstrom KD, Andrews WW, Bowles N, Towbin A Hauth JC, Goldenberg RL. Intrauterine viral infection at the time of second trimester genetic amniocentesis is not associated with post-procedure loss. Society for Gynecologic Investigation, San Diego, CA, March 1997.
71. Wenstrom KD, Owen J, Johanning G, Johnston K, Acton S, Tamura T. Are all five neural tube closure sites affected by homocysteine metabolism? Society for Perinatal Obstetricians, Miami, Florida, February 1998.
72. Wenstrom KD, Chu DC, Owen J. MSAFP, free ' hCG, and dimeric inhibin A detect aneuploidies other than Down Syndrome. Society for Perinatal Obstetricians, Miami, Florida, February 1998.
73. Bajaj P K, Wenstrom KD, DuBard M, Cliver S. Is sonographic EFW less accurate in breech presentation? Society for Perinatal Obstetricians, Miami, Florida, February 1998.
74. Biggio JR, Wenstrom KD, DuBard M. Does hydramnios indicate adverse perinatal outcome? Society for Perinatal Obstetricians, Miami, Florida, February 1998.
75. Guinn DA, Goepfert AR, Owen J, Wenstrom KD, Hauth JC. Terbutaline pump for prevention of preterm delivery: A double blind, placebo-controlled trial. Society for Perinatal Obstetricians, Miami, Florida, February 1998.

76. Brumfield CG, Cliver S, Wenstrom KD, Davis RO, Owen J, DuBard M. Dual elevations of second trimester maternal serum AFP and hCG are associated with adverse pregnancy outcomes. Society for Perinatal Obstetricians, Miami, Florida, February 1998.
77. Brumfield CG, Skinner K, Davis RO, Wenstrom KD, Owen J, Lea C. Mid-trimester fetuses with Trisomy 18: Comparing ultrasound findings to multiple marker test results. Society for Perinatal Obstetricians, Miami, Florida, February 1998.
78. Owen J, Hardin M, Wenstrom KD, Hsu C, Boots LR. Use of non-population based normative analyte values degrades the performance of the multiple marker test for Down syndrome. Society for Perinatal Obstetricians, Miami, Florida, February 1998.
79. Tamura T, Wenstrom KD, Johanning GL, Johnston KE. Changes in the incidence of heterozygous mutant of 5, 10-methylenetetrahydrofolate reductase gene among fetuses with neural-tube defects. Experimental Biology '98, San Francisco, CA, April 1998.
80. Johanning GL, Tamura T, Wenstrom KD, Johnston KE. 5,10-methylenetetrahydrofolate reductase genotypes in fetuses with neural-tube defects. Experimental Biology'98, San Francisco, CA, April 1998.
81. *Wenstrom KD, Owen J, Chu DC, Boots L. Prospective evaluation of free ' hCG and dimeric inhibin A for aneuploidy detection. Society for Maternal Fetal Medicine, San Francisco, CA, January 1999.
82. Wenstrom KD, Owen J, Boots L, DuBard M. Ultrasound dating does not improve multiple marker screening test performance. Society for Maternal Fetal Medicine, San Francisco, CA, January 1999.
83. Wenstrom KD, Descartes M, Franklin J, Cliver SP. A five year experience with Fragile X screening of high risk gravidas. Society for Maternal Fetal Medicine, San Francisco, CA, January 1999.
84. Johanning GL, Wenstrom KD, Johnston KE, Tamura T. The risk of neural-tube defects and the combination of methionine synthase and 5,10-methylenetetrahydrofolate reductase polymorphisms. FASEB 1999;13:A228.
85. Wenstrom KD, DuBard M. Does a fetal neural tube or congenital heart defect indicate increased risk of maternal hypertension? Society for Maternal Fetal Medicine, Miami, FL, February 2000.
86. Wenstrom KD, DuBard M, Owen J, Johanning G, Tamura T. The relationship of amniotic fluid homocysteine and the 677C → T MTHFR mutation to spontaneous pregnancy loss in women with a history of NTD. Society for Maternal Fetal Medicine, Miami, FL, February 2000.
87. Wenstrom KD, Wason CJ. Preconception counseling by MFM subspecialists is efficient and cost-effective. Society for Maternal Fetal Medicine, Miami, FL, February 2000. 8

88. Biggio JR, Wenstrom KD, Owen J, Oakes WJ. Fetal open spina bifida: In Utero Natural history. Society for Maternal Fetal Medicine, Reno, NV, February 2001.
89. Biggio JR, Owen J, Wenstrom KD, Oakes WJ. Can prenatal ultrasound findings predict ambulatory status in fetuses with open spina bifida (OSB)? Society for Maternal Fetal Medicine, Reno, NV, February 2001.
90. Ramsey P, Andrews, WW, Goldenberg RL, Wenstrom KD, Johnston K, Tamura T. Elevated amniotic fluid ferritin levels are associated with inflammation-related pregnancy loss following midtrimester amniocentesis. Society for Maternal Fetal Medicine, Reno, NV, February 2001.
91. Wenstrom KD, Faye-Petersen OM, Johanning GL. DNA methylation and tissue cellularity in hypoplastic left ventricles. Society for Maternal Fetal Medicine, San Francisco, February 2003.
92. Biggio JR, Owen J, Wenstrom KD, Neely C. Elevated midtrimester maternal serum dimeric inhibin-A is associated with small for gestational age infants. Society for Maternal Fetal Medicine, San Francisco, February 2003.
93. Biggio JR, Ramsey PR, Cliver SP, Lyon M, Goldenberg RL, Wenstrom KD. Elevated midtrimester amniotic fluid matrix metalloproteinase-8 levels are a marker for subsequent preterm premature rupture of membranes. Society for Maternal Fetal Medicine, San Francisco, February 2003.
94. Gala R, Biggio J, Ramsey, P, Wenstrom KD. Cystic Fibrosis Screening: To Screen or Not To Screen. Society of Maternal Fetal Medicine, New Orleans, February, 2004
95. Wenstrom KD, Cliver S, Goldenberg R, Rostrand S. In children born IUGR, normalization of weight by age 5 may be associated with hypertension. Society for Maternal Fetal Medicine, Reno, February 2005
96. Ho M, Cliver S, Wenstrom KD. Perinatal outcome in multifetal gestations complicated by intrauterine fetal demise. Society for Maternal Fetal Medicine, Miami, February 2006
97. Gyamfi C, Blumenfeld Y, Ramsey P, Foley M, Kilpatrick S, Wenstrom K. The current state of MFM fellowships: results from the SMFM fellow survey. AJOG 2009; 201 (6): S47
98. Wenstrom K, Erickson K, Schulkin J. Are generalist obstetrician -gynecologists satisfied with their MFM Consultants?: A survey . AJOG 2010; 201 (6): S202
99. Johnson J, Anderson B, Raker C, Wenstrom K. Timing of delivery with placenta previa: maternal and neonatal outcomes AJOG 2010; 201 (6): S74
100. Johnson J, Anderson B, Raker C, Wenstrom K. Elective induction at term and adverse neonatal outcomes AJOG 2010; 201 (6): S124
101. Wenstrom KD, O'Brien BO, Johnson J. Does advanced maternal age (AMA) alone increase the risk of structural fetal anomalies? AJOG 2012; 208(1): S16

FILM

1. Spellacy WN, Wenstrom KD: Cesarean Section. Produced by Davis & Geck. Shown at the 37th Annual meeting of the American College of Obstetricians and Gynecologists, Atlanta, GA, May 1989.

SELECTED LECTURES & COURSE PARTICIPATION

University of Iowa Annual Postgraduate Course -- 1991, 1992

University of Iowa Statewide Faculty Lecture Series -- 1990, 1991, 1992

Grans Rounds, Baptist Medical Center, Medical Center East, UAB Huntsville -- 1993

UAB Annual Meeting: Progress in Obstetrics and Gynecology –Speaker. 1993--1996, 1998, 1999, 2001, 2002, 2003, 2004, 2005

American College of Obstetricians and Gynecologists Postgraduate Course: "Controversies in Obstetrics" –Speaker. February 12 - 14, 1996

Visiting Professor-Michigan State University, Grand Rapids, MI -- April, 1996

Visiting Professor-Medical College of Georgia -- February 1997

University of Kentucky at Louisville –Speaker. May 1997

Society of Perinatal Obstetricians Fellows Retreat –Speaker. San Antonio Texas, October 1997

Visiting Professor, University of South Florida, Tampa -- October 1997

American College of Obstetricians and Gynecologists Postgraduate Course: Antepartum and Intrapartum Fetal Assessment –Speaker. December 1997

Society of Perinatal Obstetricians Postgraduate Course: Genetics. Course Director – January 1998

Society of Perinatal Obstetricians: Moderator, Genetics Oral Session -- January 1998

Visiting Professor-University of Kentucky at Louisville, April 1998

American College of Obstetricians and Gynecologists Postgraduate Course: Medical Complications of Pregnancy. Course Director -- July 1998

March of Dimes: Genetics Training- Speaker, Birmingham, AL - September 1998

Perinatal Social Work Conference- Speaker, Birmingham, AL - October 1998

Southwestern Gynecologic Assembly- Speaker, Dallas, TX - December 1998

Society for Maternal-Fetal Medicine (Formerly SPO): Masters' Talk, January 1999

Society for Gynecologic Investigation: Moderator, Clinical Perinatology Oral Session-March 1999

University of Utah- Speaker. Park City, Utah-March 1999

Society for Maternal Fetal Medicine Fellows Retreat –Speaker. October 1999

American College of Obstetricians and Gynecologists Postgraduate Course: "Controversies in Obstetrics"-Speaker. December 1999

Society for Maternal Fetal Medicine: Masters' Talk, February 2000

Society for Maternal Fetal Medicine: Moderator, Prematurity Session, February 2000

Society for Gynecologic Investigation: Mini Symposium on Genetics-Speaker. March 2000

Grand Rounds, University of Kentucky at Louisville, KY-April 2000

American Gynecological and Obstetrical Society Membership Presentation, September 2000

American College of Obstetricians and Gynecologists Postgraduate Course: "Medical Complications of Pregnancy" Course Director - Feb 2001

Society for Gynecologic Investigation: Moderator, Clinical Perinatology and Genetics -March 2001

Alabama ACOG Spring Meeting –Speaker. May 2001

25th Ross Seminar on Perinatal Medicine –Speaker. June 2001

Visiting Professor-Wake Forest University, Winston-Salem, NC - October 11-13, 2001

Visiting Professor- University of Alabama, Tuscaloosa, AL - October, 2001

Visiting Professor- University of Indiana, Indianapolis, IN - November , 2001

American College of Obstetricians and Gynecologists Postgraduate Course: "Controversies in Obstetrics" – Speaker. Feb 28-March 2, 2002

St. John's Mercy Medical Center, St. Louis, MO-Speaker. April , 2002

Women's Health Care, P.C., Newburgh, IN-Speaker. April, 2002

26th Ross Seminar on Perinatal Medicine –speaker. June 2002

Visiting Professor, Resident Graduation Day, University of South Florida, Tampa, FL-June 2002

North East Ohio University College of Medicine-Speaker. November 2002

Society for Maternal Fetal Medicine Fellows Talk - February, 2003

Visiting Professor, Wayne State, Detroit, MI - March 11, 2003

27th Ross Seminar on Perinatal Medicine –Speaker. June 2003

American College of Obstetricians and Gynecologists Postgraduate Course: "Controversies in Obstetrics" – Speaker. Dec 4-6, 2003

Society for Maternal-Fetal Medicine Postgraduate Course: Genetics. *Course Director* - February, 2004

28th Seminar on Perinatal Medicine-The AAP Perinatal Section and Abbott Nutrition. Speaker. June 2004

American College of Obstetricians and Gynecologists Postgraduate Course: "Controversies in Obstetrics" –Speaker. Sept 9-11, 2004

Tenth Annual Perinatal Medicine Conference, Northside Hospital, Atlanta, Georgia- Speaker. October, 2004

Visiting Professor, University of Illinois, October, 2004

Symposia Medicus 11th Annual Florida Winter Perinatal Symposium, Marco Island, FL- Speaker. November, 2004

Cleveland Society of Obstetrics and Gynecology, Cleveland Ohio January, 2005

Alabama Department of Public Health and Emory University, Satellite Conference on Folic Acid: Past, Present and Future-Speaker. January 2005

Society for Maternal-Fetal Medicine: Moderator, Genetics Oral Session- January 2005

Visiting Professor-University of Miami, Miami, Florida, March , 2005

Visiting Professor-Case Western Reserve University, Cleveland, Ohio September 2005

Vanderbilt University, Annual Perinatal Medicine Course-Speaker. December 2005

Dru Carlson Memorial Ultrasound Symposium, Los Angeles California- Speaker. January 2006

Society for Maternal-Fetal Medicine, Genetics Course- Speaker. February 2006

Society for Maternal-Fetal Medicine, Masters Series Lecture, February, 2006

American College of Obstetricians and Gynecologists Course: " Management of Multiple Gestation" – Speaker. May 9-10, 2006. Washington, D.C

29th Seminar on Perinatal Medicine-The AAP Perinatal Section and Abbott Nutrition. Speaker. June 2006

NIH conference for MFM and Neonatal Fellows. Aspen, Colorado; August, 2006

Vanderbilt University Annual Perinatal Medicine Conference: "Why our Babies Die"- Speaker. September 2006

Society for Maternal Fetal Medicine, Masters Series Lecture, February 2007

ACOG Section IX Annual Meeting- Keynote Speaker April 2007

Society for Fetal Urology, Anaheim, California- Featured Speaker, May 2007

30th Seminar on Perinatal Medicine-The AAP Perinatal Section and Abbott Nutrition. Speaker. June 2007

American Association of Pediatrics Annual NeoPrep Course- Speaker. Atlanta, GA August, 2007

CWRU Annual Perinatal Medicine Course, Cleveland, Ohio- Featured Speaker. October, 2007

Vanderbilt University Annual Perinatal Medicine Course, Nashville, TN- Speaker. November, 2007

16th Annual Ob/Gyn Ultrasound Update for Clinical Practice, Ft Lauderdale, FL- Featured Speaker. November, 2007

31st Seminar on Perinatal Medicine-The AAP Perinatal Section and Abbott Nutrition. Speaker. June 2008

Society for Maternal-Fetal Medicine, Genetics Course, Speaker, Course Director - February 2009

Stump the Professor- Speaker. ACOG annual meeting, Chicago IL May 2009

Tsunami of Genetics, Genetics Course; Brown Alpert School of Medicine, Speaker, October, 2009

Mt Auburn Hospital Annual Ob Gyne Meeting, Cambridge MA, Speaker, November, 2009

Grand Rounds, Sturdy Memorial Hospital, December, 2010

Grand Rounds, Yale University Department of OB Gyne, New Haven, CT, January 2011

New England Obstetric and Gynecologic Society Annual Meeting, Speaker, Sturbridge, MA, April 2011

Visiting Professor, University of Oklahoma, Tulsa, Resident Research Day May, 2012

Grand Rounds, Brown University School of Medicine, Women and Infants Hospital September, 2012

Phoenix Perinatal Associates and Banner Good Samaritan Hospital Annual Obstetrics Course, Phoenix, AZ. Speaker. March 2013

Central Jersey Health Consortium and the Partnership for Maternal and Child Health of Northern New Jersey, Iselin, NJ. Speaker. May 2013

Grand Rounds, Saint Peter's University Hospital, New Brunswick NJ, September 2013

Grand Rounds, Brigham and Womens Hospital, Boston MA, October 2013

Lamaze International Annual Conference, Kansas City KA. Keynote Speaker, Sept, 2014

Midwifery Week Annual Conference, Providence RI , Keynote Speaker, October, 2014

Grand Rounds, Brown University School of Medicine, Women and Infants Hospital October, 2014

American College of Obstetricians and Gynecologists Annual Meeting. Course Speaker: "Update on Noninvasive Prenatal testing (NIPT): Indications, Benefits, Limitations, and the Future" , May 4, 2015, San Francisco, CA

Maryland Perinatal Safety Center Perinatal/Neonatal Learning Network. Course Speaker, June 11, 2015

Annual National Birth Defects Prevention Network Annual Meeting, Invited Speaker. Arlington VA, October 2015

Annual Perinatal Update, Invited Speaker. Savannah Georgia, March 2016.

Society for Maternal Fetal Medicine annual meeting, Course Speaker. "Keeping the "M" in MFM"
Las Vegas NV, 2017

